AADC Deficiency clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
open to eligible people ages 24 months and up
The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency.
at UCSF
Our lead scientists for AADC Deficiency research studies include Nalin Gupta, MD.
Last updated: